Objectives: Evaluate the outcomes of adjuvant chemotherapy with epirubicin, cisplatin and xeloda for gastric cancer patients after D2 lymphadenectomy at Department of Oncology of No.108 Military Central hospital from 1/2010 to 3/2014. Methods: prospective longitudinal follow-up study on 35 gastric cancer patients. Results: The mean age was 51,8 percent 8,8 years old (30-67 years).The TNM staging in the order of II, III, stages were 71,4 percent and 28,6 percentin respectively. The most common histopathologic type was hightly and moderately adenocarcinoma (50,0 percent). Mean disease-free survival (DFS) was 34,1 + or - 3,1 months (28,0 - 40,2 months). The 1 year and 2 years DFS rates were 78,6 percent and 67,9 percent. Mean overall survival 36,9 + or - 2,5 months (31,9 - 41,8 months). The 1 year and 2 yeasr DFS rates were 92,9 percent and 78,6 percent. The main adverse effect of ECX regimen were 100 percent anorexia, nausea and hair loss; vomiting 89,3 percent, numbness 35.7 percent; hand foot syndrome 78,6 percent.
- Đăng nhập để gửi ý kiến